查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1922946

β-内酰胺类抗生素酶市场：按酵素类型、产品形式、原生动物、应用和最终用户划分 - 全球预测 2026-2032

Enzymes for B-lactam Antibiotics Market by Enzyme Type, Product Form, Source Organism, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，β-内酰胺类抗生素酶市值将达到 2.1247 亿美元，到 2026 年将成长至 2.3857 亿美元，到 2032 年将达到 4.6782 亿美元，复合年增长率为 11.93%。

关键市场统计数据
基准年 2025 2.1247亿美元
预计年份：2026年 2.3857亿美元
预测年份 2032 4.6782亿美元
复合年增长率 (%) 11.93%

为酵素创新、製程整合和监管重点如何重塑β-内酰胺类抗生素生产价值链提供了一个清晰的背景框架。

酵素在β-内酰胺类抗生素的生命週期中发挥至关重要的作用，影响合成途径、下游加工和杂质谱。酵素的发现、设计和固定化技术的进步正在重塑头孢菌素和青霉素类抗生素的生产方式，与传统化学合成相比，能够实现更具选择性的化学反应并降低对环境的影响。同时，日益严格的法规环境和对供应链稳健性的更高要求，迫使製药企业和合约研发生产力机构（CDMO）重新评估其酵素的筹资策略，尤其是在重组生产和严格的品管对于满足药典标准至关重要的领域。

计算设计趋势、日益严格的监管、永续性要求以及不断演变的外包模式正在重塑β-内酰胺类抗生素生产的酶法策略。

受技术、监管和商业性因素的驱动，β-内酰胺类抗生素生产的酵素体係正经历多项变革。首先，计算设计和定向进化技术的进步缩短了客製化生物催化剂的开发週期，加速了从发现到中试规模检验的转化。这种转变为企业内部酵素优化以及酵素开发商与製药企业之间建立策略联盟提供了更多机会，从而共同开发针对特定应用的解决方案。同时，固定化技术和连续製程的改进提高了酵素製剂的运作和可重复使用性，改变了生产设施计算其资本投资和营运成本的方式。

美国近期关税政策变化对抗生素生产中酵素原料采购、在地化和供应商合作策略的累积影响。

美国关税措施和贸易政策调整将持续到2025年，对β-内酰胺类抗生素生产所用酵素原料的采购、供应链设计和商业谈判产生重大影响。不断上涨的进口关税和相关的合规成本增加了从特定地区采购的关键中间体、试剂和酵素製剂的总到岸成本，迫使下游生产商重新评估其供应商组合和合约条款。为此，采购部门正在重新评估其库存策略，从即时采购转向增加关键酶的安全库存，同时在贸易关係更好的地区寻找替代供应商。

一个将酵素类别、应用终点、生产模式、来源地和最终用户优先顺序连结起来的多维细分框架，指南战略选择。

严谨的市场区隔观点揭示了β-内酰胺类抗生素生产中酵素创新与商业性需求的交会点。依酵素类型划分，市场涵盖β-内酰胺酶、头孢菌素酰基转移酶和青霉素G酰基转移酶。 β-内酰胺酶再分为A类、C类和D类，其中A类包括SHV和TEM。头孢菌素酰基转移酶通常由铜绿假单胞菌和变异拟桿菌产生，而青霉素G酰基转移酶则由枯草桿菌和大肠桿菌等微生物产生。这种酵素层面的细分至关重要，因为每种酵素类别和生产微生物都具有独特的反应特性、杂质风险和监管文件要求，这些都会影响下游製程设计和品质保证活动。

区域优势、监管差异和不断变化的贸易流如何影响全球製药生产基地的酵素采购、在地化决策和合作模式

区域趋势对β-内酰胺类抗生素生产的酵素来源、法规遵循和商业模式有显着影响。在美洲，一个融合了先进生物製药研发能力和成熟製药生产群集的生产生态系统已经形成，从而催生了对客製化重组酶和可扩展固定化系统的需求。监管以及与国内原材料供应商的供应链整合进一步影响供应商的选择和伙伴关係结构。同时，在欧洲、中东和非洲地区（EMEA），多样化的管理体制和严格的永续性推动了人们对绿色化学的兴趣，而成熟的生物技术和特种酵素生产能力则支持产研合作网络，加速了特定抗生素合成酶的最佳化。在亚太地区，快速的产能扩张、具有成本竞争力的生产方式以及大规模微生物发酵能力为微生物酶和重组酶提供了强大的供应基础。然而，终端使用者必须应对不同司法管辖区内品质标准和不断变化的监管要求。

透过专有的生物催化平台、合规的生产製造和一体化的开发服务，整合竞争优势，以满足製药客户的需求。

β-内酰胺酶领域的主要企业透过整合专有的生物催化平台、先进的固定化解决方案以及在头孢菌素和青霉素化学领域的深厚应用经验而脱颖而出。业界领导者投资于蛋白质工程、高通量筛检和稳健的表达系统，以提供具有客製化动力学特性、在製程条件下具有更高稳定性以及更简化的杂质谱的酶，从而简化监管申报流程。同时，专业供应商提供将酵素供应与製程开发协助、分析方法转移和放大支援相结合的综合服务，从而加快客户的生产速度并加强与供应商的长期合作关係。

制定可操作的跨产业优先事项，包括技术投资、供应商合作和供应链韧性，以加速酵素基生产并降低营运风险。

产业领导者应优先采取切实可行的措施，以充分利用技术进步并降低供应链和监管风险。首先，投资于模组化生产能力和重组表达平台，以实现灵活的规模化生产和酶批次的快速合格。这有助于降低对单一地区的依赖，并缩短对需求波动的反应时间。其次，在产品开发的早期阶段就纳入酵素的选择标准，使製程科学家、法规事务和采购团队能够在开发生命週期的早期阶段就酵素的规格、杂质容差和供应商选择进行协作。这可以最大限度地减少下游返工，并加快监管申报流程。第三，透过共同开发契约深化与奖励契约製造和酵素开发商的伙伴关係，旨在协调各方利益、共用风险并确保技术转移的顺利进行。

一项透明的调查方法结合了有针对性的初步访谈、技术案例研究和严​​谨的二手分析，以检验对相关人员的实际意义。

本分析所依据的研究结合了系统性的二手文献综述和有针对性的原始研究，以确保研究结果既有实证依据又具有实际应用价值。二手文献综述涵盖了同行评审的科学文献、专利申请、监管指导文件和上市公司披露信息，旨在梳理技术趋势、酶类别和领先的固定化技术。此外，我们也对製药公司和契约製造製造商的研发总监、製程工程师、采购负责人和品管专业人员进行了结构化访谈和咨询，以检验假设并识别在规模化生产和合格阶段出现的实际限制。

简要概述为什么在酵素法抗生素生产中整合技术、监管和商业策略将决定哪些组织能够获得可持续的优势。

β-内酰胺类抗生素生产中酵素的应用轨迹取决于技术、监管和商业性因素的共同作用，这些因素有利于适应性强的生物催化剂、稳定的供应关係以及能够最大限度减少环境影响的製程设计。蛋白质工程和固定化技术的进步正在创造显着的营运优势，但只有将酵素的选择与监管规划、供应商策略和生产系统设计相结合，才能真正实现这些创新的价值。贸易政策趋势和区域能力进一步加剧了这一局面的复杂性，因此，战略多元化和合约弹性是任何长期计划的关键要素。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. β-内酰胺类抗生素酶市场（依酵素类型划分）

  • 青霉素酰化酶
    • 青霉素G酰化酶
    • 青霉素V酰化酶
  • 头孢菌素酰基转移酶
    • 头孢菌素C酰化酶
    • 7-ACA酰化酶
  • 氨基青霉素酰化酶
    • 阿莫西林酰基转移酶
    • Ampicillin酰化酶
  • 碳青霉烯类相关酶
    • Imipenem合成酶
    • Meropenem酶
  • 辅助酵素
    • 酯酶
    • 酰胺酶
    • β-内酰胺酶

9. β-内酰胺类抗生素酶市场（依产品形式划分）

  • 游离酶
  • 固定化酵素
    • 吸附
    • 共用价键
    • 封装
    • 已附上

10. β-内酰胺类抗生素用酵素市场（依来源划分）

  • 微生物来源
    • 细菌来源
      • 大肠桿菌
      • 芽孢桿菌
      • 链霉菌
    • 真菌
      • 曲菌
      • 青霉菌
  • 动物源性
    • 源自猪
    • 牛源
  • 植物来源
  • 重组/基因修饰
    • 基因工程改造的细菌宿主
    • 酵母宿主
    • 真菌宿主

11. 依应用分類的β-内酰胺类抗生素酶市场

  • 头孢菌素合成
    • 头孢羟氨芐
    • 头孢氨芐
  • 青霉素合成
    • 青霉素G
    • 青霉素V

12. 依最终用户分類的β-内酰胺类抗生素酶市场

  • 契约製造组织
  • 製药公司

13. 各地区β-内酰胺类抗生素酶市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. β-内酰胺类抗生素酶市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国β-内酰胺类抗生素酶市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国β-内酰胺类抗生素酶市场

第十七章 中国β-内酰胺类抗生素酶市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amicogen, Inc.
  • Aurobindo Pharma Limited
  • Biosynth AG
  • Centrient Pharmaceuticals Netherlands BV
  • Cipla Limited
  • Creative Enzymes, Inc.
  • Eucodis Bioscience GmbH
  • Fermenta Biotech Limited
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Limited
Product Code: MRR-867BED9A9E75

The Enzymes for B-lactam Antibiotics Market was valued at USD 212.47 million in 2025 and is projected to grow to USD 238.57 million in 2026, with a CAGR of 11.93%, reaching USD 467.82 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 212.47 million
Estimated Year [2026] USD 238.57 million
Forecast Year [2032] USD 467.82 million
CAGR (%) 11.93%

A clear contextual framing of how enzyme innovation, process integration, and regulatory priorities are redefining B-lactam antibiotic manufacturing value chains

Enzymes play an indispensable role in the life cycle of B-lactam antibiotics, influencing synthesis routes, downstream processing, and impurity profiles. Advances in enzyme discovery, engineering, and immobilization techniques have reshaped how cephalosporins and penicillins are manufactured, enabling more selective chemistries and reduced environmental footprints when compared with traditional chemical syntheses. In parallel, the regulatory environment and heightened scrutiny on supply chain robustness have pushed pharmaceutical manufacturers and contract development and manufacturing organizations to re-evaluate enzyme sourcing strategies, particularly where recombinant production and stringent quality control are essential to meet pharmacopeial standards.

Recent progress in protein engineering has accelerated the adaptation of enzymes to industrial conditions, improving thermostability, solvent tolerance, and substrate specificity, while process intensification and continuous manufacturing paradigms are creating new operational use cases for immobilized biocatalysts. Consequently, enzyme selection is no longer solely a biochemical decision but a cross-functional one that must incorporate considerations of scale-up, regulatory compliance, cost-to-serve, and strategic supplier relationships. This introduction sets the stage for a deeper examination of transformative shifts, regulatory and trade pressures, segmentation-driven opportunities, and region-specific dynamics that together define the current competitive landscape for enzymes applied to B-lactam antibiotic production.

How computational design, regulatory stringency, sustainability demands, and evolving outsourcing models are reshaping enzyme strategies across B-lactam antibiotic production

The landscape for enzymes in B-lactam antibiotic production is undergoing several transformative shifts driven by technological, regulatory, and commercial forces. First, advances in computational design and directed evolution are compressing development cycles for customized biocatalysts, enabling faster translation from discovery to pilot-scale validation. This shift is creating more opportunities for in-house enzyme optimization as well as strategic partnerships between enzyme developers and pharmaceutical manufacturers to co-develop application-specific solutions. At the same time, improvements in immobilization and continuous processing are increasing the operational lifespan and reusability of enzyme preparations, thereby altering capital utilization and operating expenditure calculations for production facilities.

Second, regulatory emphasis on product quality and supply chain transparency has incentivized investment in recombinant expression systems and traceable raw material sourcing. Consequently, organizations are prioritizing enzymes with robust characterization data, defined impurity profiles, and well-documented manufacturing controls. Third, sustainability and circularity imperatives are reshaping process design choices. The adoption of greener synthesis routes using enzymes reduces hazardous waste and energy consumption relative to classical chemical processes, making enzyme-enabled manufacturing a preferred option for companies seeking to meet corporate environmental targets and respond to stakeholder expectations. Finally, the maturation of contract manufacturing ecosystems that specialize in biocatalytic processes is creating new commercial models where pharmaceutical companies outsource complex enzymatic steps to specialist providers, thereby shifting the locus of investment and expertise within the value chain. Together, these changes are producing a dynamic environment where technological differentiation, regulatory alignment, and commercial partnerships determine competitive advantage.

The cumulative consequences of recent United States tariff shifts on procurement, localization, and supplier collaboration strategies for enzymatic inputs in antibiotic manufacturing

Tariff actions and trade policy adjustments in the United States through 2025 have had a meaningful effect on procurement, supply chain design, and commercial negotiations for enzymatic inputs used in B-lactam antibiotic manufacturing. Rising import duties and associated compliance costs have increased the total landed cost of key intermediates, reagents, and enzyme preparations sourced from certain jurisdictions, prompting downstream manufacturers to reassess supplier portfolios and contractual terms. In response, procurement teams have rebalanced inventory strategies, moving from just-in-time sourcing toward higher safety stocks for critical enzymes while simultaneously seeking alternative suppliers in jurisdictions with more favorable trade relationships.

Beyond immediate cost pressures, tariffs have catalyzed strategic shifts toward localization and dual-sourcing arrangements. Pharmaceutical firms and CMOs have accelerated investments in regional production capabilities and validated local supply chains to reduce exposure to tariff volatility and customs delays. This localization trend has also heightened the value of recombinant expression platforms and local biomanufacturing know-how, since domestic production of enzyme inputs can mitigate tariff impacts and improve responsiveness to regulatory inspections. Moreover, the increased transactional friction has amplified the importance of long-term supplier contracts and collaborative development agreements that embed risk-sharing mechanisms and price-stabilization clauses. In sum, the cumulative effect of tariff policies has been to increase strategic emphasis on supply resilience, foster nearshoring where feasible, and drive more integrated commercial relationships between enzyme developers, suppliers, and end users.

A multidimensional segmentation framework connecting enzyme classes, application endpoints, production formats, source origins, and end-user priorities to inform strategic choices

A rigorous segmentation-based perspective illuminates where enzyme innovation and commercial demand intersect within B-lactam antibiotic production. When considering enzyme type, the market encompasses beta-lactamase, cephalosporin acylase, and penicillin G acylase, with beta-lactamase further differentiated across Class A, Class C, and Class D, and Class A including SHV and TEM types, while cephalosporin acylase sources are exemplified by Pseudomonas aeruginosa and Variovorax paradoxus and penicillin G acylase is produced from organisms such as Bacillus subtilis and Escherichia coli. This enzyme-level granularity matters because each enzyme class and producer organism carries distinct kinetic properties, impurity risks, and regulatory documentation requirements that influence downstream process design and quality assurance activities.

Moving to application-based segmentation, demand is shaped by cephalosporin synthesis and penicillin synthesis, with cephalosporin routes targeting molecules like cefadroxil and cephalexin while penicillin pathways focus on penicillin G and penicillin V. These application endpoints dictate substrate specificities, reaction conditions, and purification strategies and therefore determine which enzyme types and production formats are most appropriate for a given manufacturing scenario. Considering product form, free enzymes and immobilized enzymes present different operational trade-offs; immobilized preparations rely on techniques such as adsorption, covalent bonding, encapsulation, and entrapment to enhance reusability and stability, while free enzymes may offer greater initial activity but shorter operational lifetimes. In terms of source, the choice between microbial and recombinant origins affects traceability, scalability, and regulatory dossiers. Finally, end-user segmentation between contract manufacturing organizations and pharmaceutical manufacturers reveals divergent procurement behaviors: CMOs emphasize process robustness and cost-per-batch optimization, whereas pharmaceutical companies may prioritize intellectual property protection, product-specific validation, and long-term supply certainty. Together, these segmentation axes provide a multidimensional framework to align enzyme selection, process development, and commercial engagement strategies with the specific technical and business requirements of different stakeholders.

How regional strengths, regulatory variation, and evolving trade flows shape enzyme sourcing, localization decisions, and collaborative models across global pharmaceutical production hubs

Regional dynamics exert a powerful influence on enzyme sourcing, regulatory compliance, and commercial models for B-lactam antibiotic manufacture. In the Americas, manufacturing ecosystems combine advanced biologics R&D capabilities with established pharmaceutical production clusters, creating demand for both customized recombinant enzymes and scalable immobilized systems; regulatory scrutiny and supply chain integration with domestic raw material suppliers further shape provider selection and partnership structures. Meanwhile, in Europe, Middle East & Africa, diverse regulatory regimes and strong sustainability mandates drive interest in green chemistry approaches, and established capacity in biotechnology and specialty enzyme production supports collaborative networks between academic centers and industry that help accelerate enzyme optimization for specific antibiotic syntheses. In the Asia-Pacific region, rapid capacity expansion, cost-competitive manufacturing, and large-scale microbial fermentation capabilities underpin a robust supply base for both microbial and recombinant enzymes, although end users must navigate heterogeneity in quality standards and evolving regulatory expectations across jurisdictions.

Transitional trade flows and regional policy differences influence decisions around localization, inventory strategy, and contractual structuring. For example, companies active across multiple regions frequently adopt hybrid sourcing strategies that combine local production in strategic markets with centralized high-value enzyme manufacturing to capitalize on technical expertise while reducing tariff and logistics exposure. Additionally, regional centers of excellence for immobilization technologies, protein engineering, and process intensification are enabling knowledge transfer across borders, thereby accelerating adoption of best practices and creating new commercial opportunities for value-added enzyme service providers. Overall, an appreciation of how regional strengths and constraints interact is essential to designing resilient enzyme supply chains and to aligning R&D investments with market opportunities.

A synthesis of competitive differentiation through proprietary biocatalyst platforms, regulatory-grade manufacturing, and integrated development services to meet pharmaceutical customer needs

Key companies in the enzyme-for-B-lactam space are differentiating through a combination of proprietary biocatalyst platforms, advanced immobilization solutions, and deep application know-how for cephalosporin and penicillin chemistries. Industry leaders are investing in protein engineering, high-throughput screening, and robust expression systems to deliver enzymes with tailored kinetics, improved stability under process conditions, and simplified impurity profiles that facilitate regulatory submissions. At the same time, specialist providers are creating integrated service offerings that combine enzyme supply with process development support, analytical method transfer, and scale-up assistance, thereby reducing time-to-production for customers and enhancing long-term supplier relationships.

Competitive strategies also emphasize strategic partnerships and co-development agreements with pharmaceutical companies and CMOs to align enzyme design with product-specific manufacturing requirements. Furthermore, value differentiation often arises from manufacturing footprint and quality systems: firms with validated recombinant production capabilities, certified quality management systems, and demonstrated regulatory inspection histories can command premium positioning when end users require confidence in supply and documentation. Technology providers that offer flexible product forms-ranging from high-activity free enzyme concentrates to immobilized formulations optimized for continuous reactors-are capturing demand from customers pursuing process intensification. In short, success in this sector depends on marrying technical excellence with service-oriented delivery models and regulatory-grade manufacturing practices.

Actionable, cross-functional priorities for technology investment, supplier collaboration, and supply chain resilience to accelerate enzyme-enabled production and reduce operational risk

Industry leaders should pursue a set of actionable priorities to capitalize on technological advances and to mitigate supply chain and regulatory risks. First, invest in modular production capabilities and recombinant expression platforms that enable flexible scaling and rapid qualification of enzyme lots; this reduces dependence on single geographies and shortens response times to demand fluctuations. Second, embed enzyme selection criteria into earlier stages of product development so that process scientists, regulatory affairs, and procurement collaborate on enzyme specifications, impurity expectations, and supplier qualification early in the development lifecycle. Doing so minimizes downstream rework and accelerates regulatory filings. Third, deepen partnerships with contract manufacturers and enzyme developers through co-development agreements that align incentives, share risk, and ensure technology transfer readiness.

Fourth, prioritize immobilization and continuous processing trials to evaluate total cost-of-ownership under anticipated production scenarios; early piloting can reveal throughput and durability advantages that translate into facility-level operational savings. Fifth, strengthen geographic diversification by establishing validated secondary supply sources or local production where tariff and trade policies create exposure, and incorporate contractual safeguards such as price-stabilization clauses and contingency supply commitments. Finally, augment technical investments with governance and quality frameworks that support traceability, batch-level documentation, and readiness for regulatory inspections. Together, these measures will enhance resilience, reduce time-to-market, and create competitive differentiation for organizations engaged in enzymatic B-lactam antibiotic production.

A transparent research approach combining targeted primary interviews, technical case studies, and rigorous secondary analysis to validate practical implications for stakeholders

The research underpinning this analysis combined systematic secondary review with targeted primary engagements to ensure findings are evidence-based and operationally relevant. Secondary analysis encompassed peer-reviewed scientific literature, patent filings, regulatory guidance documents, and public company disclosures to map technological trends, enzyme classes, and prevalent immobilization techniques. This foundation was augmented by structured interviews and consultations with R&D leaders, process engineers, procurement professionals, and quality experts across pharmaceutical companies and contract manufacturers to validate assumptions and surface practical constraints encountered during scale-up and qualification.

In addition, laboratory-level case studies and anonymized project retrospectives provided insight into performance trade-offs among free and immobilized enzyme formats, while comparative assessments of recombinant versus microbial sourcing clarified considerations around traceability and scalability. Data synthesis employed qualitative coding and triangulation to reconcile divergent viewpoints and to identify robust themes. Findings were reviewed by independent subject matter experts to ensure technical accuracy and commercial relevance. Throughout the research process, attention was paid to transparency of methodology, reproducibility of key observations, and the articulation of actionable implications for decision-makers.

A concise synthesis of why integrated technical, regulatory, and commercial strategies will determine which organizations capture durable advantages in enzyme-enabled antibiotic manufacturing

The trajectory of enzyme utilization in B-lactam antibiotic manufacturing is defined by converging technical, regulatory, and commercial forces that favor adaptable biocatalysts, robust supply relationships, and process designs that minimize environmental impact. Advances in protein engineering and immobilization technologies are creating compelling operational advantages, yet the full value of these innovations is realized only when enzyme selection is integrated with regulatory planning, supplier strategy, and manufacturing system design. Trade policy dynamics and regional capabilities further complicate the landscape, making strategic diversification and contractual resilience essential components of any long-term plan.

Looking ahead, organizations that couple technical investments with collaborative commercial models will be best positioned to turn enzyme-enabled process improvements into sustained competitive benefit. Embedding enzyme considerations early in product development, piloting immobilized continuous processes, and securing validated, geographically diversified supply chains will collectively reduce operational risk and unlock efficiency gains. In summary, the industry is at an inflection point where thoughtful alignment of science, operations, and commercial strategy will determine which players capture the next wave of improvements in B-lactam antibiotic production.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enzymes for B-lactam Antibiotics Market, by Enzyme Type

  • 8.1. Penicillin Acylases
    • 8.1.1. Penicillin G Acylase
    • 8.1.2. Penicillin V Acylase
  • 8.2. Cephalosporin Acylases
    • 8.2.1. Cephalosporin C Acylase
    • 8.2.2. 7-ACA Acylase
  • 8.3. Aminopenicillin Acylases
    • 8.3.1. Amoxicillin Acylase
    • 8.3.2. Ampicillin Acylase
  • 8.4. Carbapenem-related Enzymes
    • 8.4.1. Imipenem Synthesis Enzymes
    • 8.4.2. Meropenem Synthesis Enzymes
  • 8.5. Auxiliary Enzymes
    • 8.5.1. Esterases
    • 8.5.2. Amidases
    • 8.5.3. B-lactamases

9. Enzymes for B-lactam Antibiotics Market, by Product Form

  • 9.1. Free Enzyme
  • 9.2. Immobilized Enzyme
    • 9.2.1. Adsorption
    • 9.2.2. Covalent Bonding
    • 9.2.3. Encapsulation
    • 9.2.4. Entrapment

10. Enzymes for B-lactam Antibiotics Market, by Source Organism

  • 10.1. Microbial
    • 10.1.1. Bacterial
      • 10.1.1.1. Escherichia coli
      • 10.1.1.2. Bacillus Species
      • 10.1.1.3. Streptomyces Species
    • 10.1.2. Fungal
      • 10.1.2.1. Aspergillus Species
      • 10.1.2.2. Penicillium Species
  • 10.2. Animal
    • 10.2.1. Porcine
    • 10.2.2. Bovine
  • 10.3. Plant
  • 10.4. Recombinant / Engineered
    • 10.4.1. Genetically Modified Bacterial Hosts
    • 10.4.2. Yeast Hosts
    • 10.4.3. Fungal Hosts

11. Enzymes for B-lactam Antibiotics Market, by Application

  • 11.1. Cephalosporin Synthesis
    • 11.1.1. Cefadroxil
    • 11.1.2. Cephalexin
  • 11.2. Penicillin Synthesis
    • 11.2.1. Penicillin G
    • 11.2.2. Penicillin V

12. Enzymes for B-lactam Antibiotics Market, by End User

  • 12.1. Contract Manufacturing Organizations
  • 12.2. Pharmaceutical Manufacturers

13. Enzymes for B-lactam Antibiotics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Enzymes for B-lactam Antibiotics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Enzymes for B-lactam Antibiotics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Enzymes for B-lactam Antibiotics Market

17. China Enzymes for B-lactam Antibiotics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amicogen, Inc.
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Biosynth AG
  • 18.9. Centrient Pharmaceuticals Netherlands B.V.
  • 18.10. Cipla Limited
  • 18.11. Creative Enzymes, Inc.
  • 18.12. Eucodis Bioscience GmbH
  • 18.13. Fermenta Biotech Limited
  • 18.14. GlaxoSmithKline plc
  • 18.15. Hikma Pharmaceuticals PLC
  • 18.16. Lupin Limited
  • 18.17. Merck & Co., Inc.
  • 18.18. Merck KGaA
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Sanofi
  • 18.22. Sun Pharmaceutical Industries Limited
  • 18.23. Teva Pharmaceutical Industries Ltd.
  • 18.24. Wockhardt Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN G ACYLASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN G ACYLASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN G ACYLASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN V ACYLASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN V ACYLASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN V ACYLASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN C ACYLASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN C ACYLASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN C ACYLASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY 7-ACA ACYLASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY 7-ACA ACYLASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY 7-ACA ACYLASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN ACYLASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN ACYLASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN ACYLASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMPICILLIN ACYLASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMPICILLIN ACYLASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMPICILLIN ACYLASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMIPENEM SYNTHESIS ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMIPENEM SYNTHESIS ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMIPENEM SYNTHESIS ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MEROPENEM SYNTHESIS ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MEROPENEM SYNTHESIS ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MEROPENEM SYNTHESIS ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ESTERASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ESTERASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ESTERASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMIDASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMIDASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMIDASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY B-LACTAMASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY B-LACTAMASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY B-LACTAMASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FREE ENZYME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FREE ENZYME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FREE ENZYME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ADSORPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ADSORPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ADSORPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COVALENT BONDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COVALENT BONDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COVALENT BONDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENCAPSULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENCAPSULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENCAPSULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENTRAPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENTRAPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENTRAPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACILLUS SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACILLUS SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACILLUS SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY STREPTOMYCES SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY STREPTOMYCES SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY STREPTOMYCES SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIUM SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIUM SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIUM SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PORCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PORCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PORCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BOVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BOVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BOVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY GENETICALLY MODIFIED BACTERIAL HOSTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY GENETICALLY MODIFIED BACTERIAL HOSTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY GENETICALLY MODIFIED BACTERIAL HOSTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY YEAST HOSTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY YEAST HOSTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY YEAST HOSTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL HOSTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL HOSTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL HOSTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEFADROXIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEFADROXIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEFADROXIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALEXIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALEXIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALEXIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY SOURCE ORGANISM, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ANIMAL, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY RECOMBINANT / ENGINEERED, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY ENZYME TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AMINOPENICILLIN ACYLASES, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY CARBAPENEM-RELATED ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY AUXILIARY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA ENZYMES FOR B-LACTAM ANTIBIOTICS MARKET SIZE, BY IMMOBILIZED ENZYME, 2018-20